XGN - Exagen Inc Stock Price, Fair Value and News

1.38USD-0.02 (-1.43%)Market Closed

Market Summary

USD1.38-0.02

Market Closed

-1.43%

XGN Stock Price

View Fullscreen

XGN RSI Chart

XGN Valuation

Market Cap

24.1M

Price/Earnings (Trailing)

-1.02

Price/Sales (Trailing)

0.46

Price/Free Cashflow

-1.58

XGN Price/Sales (Trailing)

XGN Profitability

Return on Equity

-104.38%

Return on Assets

-41.6%

Free Cashflow Yield

-63.36%

XGN Fundamentals

XGN Revenue

Revenue (TTM)

52.5M

Rev. Growth (Yr)

7.23%

Rev. Growth (Qtr)

2.6%

XGN Earnings

Earnings (TTM)

-23.7M

Earnings Growth (Yr)

61.17%

Earnings Growth (Qtr)

-2.92%

Breaking Down XGN Revenue

Last 7 days

-2.8%

Last 30 days

-13.0%

Last 90 days

-27.5%

Trailing 12 Months

-44%

How does XGN drawdown profile look like?

XGN Financial Health

Current Ratio

4.02

Debt/Equity

0.85

Debt/Cashflow

-0.75

XGN Investor Care

Buy Backs (1Y)

0.21%

Diluted EPS (TTM)

-1.34

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	46.4M	52.9M	51.6M	52.5M
2022	48.1M	42.9M	45.4M	45.6M
2021	43.0M	46.8M	48.3M	48.3M
2020	40.7M	39.2M	39.5M	42.0M
2019	34.4M	36.4M	38.4M	40.4M
2018	0	0	0	32.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Exagen Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 04, 2024	adawi kamal	sold	-24,406	1.90917	-12,784	cfo and corporate secretary
Feb 29, 2024	aballi john	acquired	18,725	1.91	9,804	president and ceo
Feb 20, 2024	adawi kamal	acquired	-	-	75,000	cfo and corporate secretary
Feb 20, 2024	aballi john	acquired	-	-	175,000	president and ceo
Feb 06, 2024	adawi kamal	sold	-13,133	1.9491	-6,738	cfo and corporate secretary
Oct 17, 2023	aballi john	sold	-59,017	1.7451	-33,819	president and ceo
Aug 31, 2023	aballi john	acquired	20,998	2.142	9,803	president and ceo
Jun 15, 2023	tullis james l l	bought	519	3.1105	167	-
Mar 02, 2023	adawi kamal	sold	-8,431	2.2993	-3,667	cfo and corporate secretary
Mar 02, 2023	hazeltine mark	sold	-	-	-3,667	chief business officer

Which funds bought or sold XGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	WASATCH ADVISORS LP	reduced	-7.46	-440,950	1,251,160	0.01%
Apr 18, 2024	Penbrook Management LLC	added	1.32	-28,694	121,969	0.08%
Apr 17, 2024	First Bank & Trust	unchanged	-	-5,407	21,494	-%
Apr 15, 2024	Palumbo Wealth Management LLC	new	-	29,004	29,004	0.01%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-211,105	976,979	-%
Feb 15, 2024	BARCLAYS PLC	unchanged	-	-2,000	10,000	-%
Feb 15, 2024	State of Wyoming	sold off	-100	-1,590	-	-%
Feb 15, 2024	Nantahala Capital Management, LLC	added	81.93	128,173	386,554	0.01%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	reduced	-11.54	-4,493	11,992	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	41,263	41,263	-%

Are Funds Buying or Selling XGN?

Are funds buying XGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own XGN

No. of Funds

Unveiling Exagen Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	rtw investments, lp	8.8%	1,504,602	SC 13G/A
Feb 14, 2024	lytton laurence w	6.8%	1,153,488	SC 13G/A
Feb 13, 2024	stonepine capital management, llc	3.9%	669,684	SC 13G/A
Feb 13, 2024	tullis dickerson capital focus iii, l.p.	6.5%	1,112,357	SC 13G/A
Feb 09, 2024	wasatch advisors lp	-	0	SC 13G/A
Feb 02, 2024	cowen financial products llc	5.27%	898,630	SC 13G/A
Jan 22, 2024	nmsic co-investment fund, l.p.	13.55%	2,308,958	SC 13G/A
Feb 14, 2023	rtw investments, lp	8.4%	1,364,336	SC 13G/A
Feb 13, 2023	stonepine capital management, llc	5.2%	854,042	SC 13G/A
Feb 13, 2023	lytton laurence w	5.3%	871,181	SC 13G/A

Recent SEC filings of Exagen Inc

View All Filings

Date Filed	Form Type	Document
Mar 18, 2024	8-K	Current Report
Mar 18, 2024	10-K	Annual Report
Mar 06, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Feb 22, 2024	4	Insider Trading
Feb 22, 2024	4	Insider Trading
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Exagen Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	174.4B	23.7B	-0.66%	-0.48%	39.62	7.35	-8.94%	-35.72%
IDXX	41.1B	3.7B	-6.96%	-1.95%	48.61	11.22	8.72%	24.44%
A	40.3B	6.7B	-5.62%	0.50%	32.59	5.98	-2.81%	-6.58%
DGX	15.2B	9.3B	5.76%	-6.69%	17.84	1.65	-6.38%	-9.73%
CRL	12.3B	4.1B	-11.91%	17.80%	25.9	2.98	3.86%	-2.39%
MEDP	11.5B	2.0B	-0.40%	117.42%	36.88	5.87	25.57%	21.62%
EXAS	11.5B	2.5B	2.30%	-4.05%	-56.23	4.59	19.93%	67.26%
NTRA	11.0B	1.1B	-1.39%	71.77%	-25.41	10.21	31.99%	20.63%
MID-CAP
NEOG	2.7B	929.2M	-19.07%	-29.09%	1.7K	2.87	28.93%	111.61%
GH	2.2B	563.9M	0.58%	-24.79%	-4.59	3.91	25.45%	26.76%
SMALL-CAP
CDNA	426.1M	280.3M	-13.73%	-2.49%	-2.24	1.52	-12.89%	-148.37%
ACRS	83.0M	31.2M	6.09%	-86.56%	-0.94	2.66	5.03%	-1.81%
AWH	41.8M	9.2M	-7.12%	-37.22%	-2.51	4.57	11.85%	44.12%
APDN	4.9M	9.0M	-42.00%	-72.12%	-0.68	0.55	-53.31%	2.21%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Exagen Inc News

Latest updates

Exagen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	2.6%	13,765	13,416	14,137	11,230	12,837	14,726	7,606	10,394	12,689	12,251	12,772	10,587	12,668	10,775	8,948	9,584	10,214	10,439	10,474	9,260	8,742
Costs and Expenses	2.3%	18,912	18,485	19,052	18,936	27,328	22,543	21,670	20,073	18,943	18,755	18,514	16,154	15,429	14,561	12,365	14,805	13,072	12,596	12,884	11,134	-
S&GA Expenses	7.4%	12,216	11,375	11,953	11,884	12,812	14,151	12,903	12,152	11,802	11,528	11,171	10,040	9,929	9,202	8,276	9,626	7,915	7,306	7,302	6,179	-
R&D Expenses	-23.1%	1,076	1,400	1,263	1,126	2,701	2,382	2,689	2,104	2,202	1,740	1,892	1,403	1,165	1,018	751	634	566	507	590	513	-
Interest Expenses	1.6%	566	557	574	638	626	618	606	598	639	678	663	645	652	647	635	631	771	909	910	901	-
Income Taxes	-	-	-	-	-	-	-	-	-	175	-	-	-	39.00	-	-	-118	25.00	-	-	-	-
Net Income	-2.9%	-5,573	-5,415	-5,013	-7,688	-14,354	-8,096	-14,665	-10,272	-7,053	-7,179	-6,410	-6,209	-3,453	-4,308	-3,363	-5,563	-3,408	-3,141	-2,785	-2,704	-1,317
Net Income Margin	28.3%	-0.45*	-0.63*	-0.66*	-0.97*	-1.04*	-0.88*	-0.91*	-0.64*	-0.56*	-0.48*	-0.44*	-0.40*	-0.40*	-	-	-	-	-	-	-	-
Free Cashflow	383.3%	8,243	-2,910	-10,478	-10,145	-6,140	-7,561	-13,100	-9,661	-7,111	-5,885	-5,164	-4,479	-3,904	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	-6.5%	57.00	61.00	64.00	79.00	86.00	102	107	122	123	128	133	138	78.00	80.00	81.00	85.00	88.00	93.00	29.00
Current Assets	-2.2%	48.00	49.00	51.00	66.00	73.00	82.00	88.00	104	113	118	125	129	71.00	73.00	73.00	78.00	81.00	86.00	21.00
Cash Equivalents	28.3%	36.00	28.00	31.00	52.00	62.00	69.00	76.00	90.00	100	107	113	118	58.00	62.00	64.00	69.00	72.00	78.00	13.00
Net PPE	-	-	-	-	-	-	-	-	-	5.00	3.00	3.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	2.00
Goodwill	-	-	-	-	-	-	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00
Liabilities	2.5%	34.00	33.00	32.00	43.00	44.00	45.00	44.00	46.00	39.00	37.00	37.00	36.00	37.00	36.00	33.00	34.00	33.00	34.00	36.00
Current Liabilities	17.6%	12.00	10.00	9.00	9.00	10.00	11.00	10.00	12.00	9.00	8.00	8.00	8.00	9.00	8.00	6.00	7.00	6.00	8.00	9.00
Long Term Debt	0.2%	19.00	19.00	19.00	29.00	29.00	28.00	28.00	28.00	27.00	27.00	27.00	27.00	27.00	26.00	26.00	26.00	26.00	26.00	25.00
LT Debt, Current	1.1%	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	0.2%	19.00	19.00	19.00	29.00	29.00	28.00	28.00	28.00	27.00	27.00	27.00	27.00	27.00	26.00	26.00	26.00	26.00	26.00	25.00
Shareholder's Equity	-17.5%	23.00	28.00	32.00	36.00	42.00	56.00	63.00	76.00	85.00	91.00	96.00	101	42.00	44.00	48.00	51.00	56.00	59.00	-
Retained Earnings	-2.1%	-279	-273	-268	-263	-255	-241	-233	-218	-208	-201	-193	-187	-181	-177	-173	-170	-164	-161	-152
Additional Paid-In Capital	0.3%	302	301	300	299	298	297	296	295	293	292	290	289	223	222	221	221	220	220	41.00
Shares Outstanding	0.7%	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	16.00	16.00	15.00	13.00	13.00	-	-	-	-	-	-
Float	-	-	-	37.00	-	-	-	62.00	-	-	-	158	-	-	-	83.00	-	-	105	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	387.1%	8,349	-2,908	-10,154	-9,749	-5,734	-6,682	-11,154	-8,574	-6,047	-5,460	-4,450	-4,312	-3,899	-2,128	-4,756	-3,301	-3,927	-1,666	-2,168	-1,950	-
Share Based Compensation	-14.3%	763	890	978	986	582	1,306	1,440	1,376	1,177	1,354	1,285	912	817	799	647	431	487	62.00	11.00	12.00	-
Cashflow From Investing	-4100.0%	-84.00	-2.00	-322	-396	-406	-879	-1,946	-1,087	-1,064	-475	-714	-167	-5.00	-213	-153	-84.00	-26.00	-2.00	288	-363	-
Cashflow From Financing	-103.7%	-220	-108	-10,242	-62.00	-173	-22.00	-264	-30.00	-213	125	-310	65,081	-82.00	75.00	-39.00	-51.00	-1,791	63,259	3,790	3,476	-

XGN Income Statement

2023-12-31

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
Statements of Operations - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 52,548	$ 45,563
Operating expenses:
Costs of revenue	23,092	24,214
Selling, general and administrative expenses	47,428	52,018
Research and development expenses	4,865	9,876
Goodwill impairment	0	5,506
Total operating expenses	75,385	91,614
Loss from operations	(22,837)	(46,051)
Interest expense	(2,335)	(2,448)
Interest income	1,516	830
Loss before income taxes	(23,656)	(47,669)
Income tax (expense) benefit	(33)	282
Net loss	$ (23,689)	$ (47,387)
Net loss per share, basic (in dollars per share)	$ (1.34)	$ (2.77)
Net loss per share, diluted (in dollars per share)	$ (1.34)	$ (2.77)
Weighted-average number of shares used to compute net loss per share, basic (in shares)	17,679,467	17,082,348
Weighted-average number of shares used to compute net loss per share, diluted (in shares)	17,679,467	17,082,348

XGN Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 36,493	$ 62,391
Accounts receivable, net	6,551	6,077
Prepaid expenses and other current assets	4,797	4,143
Total current assets	47,841	72,611
Property and equipment, net	5,201	8,197
Operating lease right-of-use assets	3,286	4,885
Other assets	616	528
Total assets	56,944	86,221
Current liabilities:
Accounts payable	3,131	3,046
Operating lease liabilities	976	1,040
Borrowings-current portion	264	190
Accrued and other current liabilities	7,531	5,347
Total current liabilities	11,902	9,623
Borrowings-non-current portion, net of discounts and debt issuance costs	19,231	28,778
Non-current operating lease liabilities	2,760	4,493
Other non-current liabilities	357	867
Total liabilities	34,250	43,761
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2023 and December 31, 2022	0	0
Common stock, $0.001 par value per share; 200,000,000 shares authorized at December 31, 2023 and December 31, 2022; 17,045,954 and 16,549,984 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	17	17
Additional paid-in capital	301,893	297,970
Accumulated deficit	(279,216)	(255,527)
Total stockholders' equity	22,694	42,460
Total liabilities and stockholders' equity	$ 56,944	$ 86,221

About Exagen Inc

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

CEO	Mr. John Aballi
WEBSITE	exagen.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	199

Exagen Inc Frequently Asked Questions

What is the ticker symbol for Exagen Inc? What does XGN stand for in stocks?

XGN is the stock ticker symbol of Exagen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Exagen Inc (XGN)?

As of Tue Apr 23 2024, market cap of Exagen Inc is 24.13 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XGN stock?

You can check XGN's fair value in chart for subscribers.

What is the fair value of XGN stock?

You can check XGN's fair value in chart for subscribers. The fair value of Exagen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Exagen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Exagen Inc a good stock to buy?

The fair value guage provides a quick view whether XGN is over valued or under valued. Whether Exagen Inc is cheap or expensive depends on the assumptions which impact Exagen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XGN.

What is Exagen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, XGN's PE ratio (Price to Earnings) is -1.02 and Price to Sales (PS) ratio is 0.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XGN PE ratio will change depending on the future growth rate expectations of investors.